Please ensure Javascript is enabled for purposes of website accessibility

Celgene's Final Earnings Report?

By Brian Orelli, PhD – Apr 29, 2019 at 3:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Depending on when in the third quarter its deal with Bristol-Myers Squibb closes, this could be the last report of the beloved big biotech.

As it prepares to be acquired by Bristol-Myers Squibb (BMY 0.13%), Celgene (CELG) continued its solid performance, racking up double-digit sales growth in the first quarter.

Celgene results: The raw numbers


Q1 2019

Q1 2018

Year-Over-Year Change


$4.025 billion

$3.538 billion


Income from operations

$1.710 billion

$218 million


Earnings per share (EPS)




Adjusted EPS




Data source: Celgene.

What happened with Celgene this quarter?

  • Driving most of the growth, sales of Celgene's top-selling blood-cancer drug Revlimid jumped 15% year over year.
  • Sales of its other important blood-cancer drug, Pomalyst, which goes by Imnovid in some markets, increased 23% year over year, driven by a 30% increase in U.S. sales. International sales increased a respectable 9% year over year.
  • Anti-inflammatory Otezla saw sales increase 10%, driven by international sales of 14%, while U.S. sales increased 9% year over year.
  • Sales of Abraxane, which treats solid tumors, increased 9% year over year; U.S. sales were up 23% year over year.
  • On the pipeline front, earlier this month, Celgene and its partner Acceleron Pharma (XLRN) submitted a marketing application to the Food and Drug Administration for luspatercept, for a group of blood cancers called myelodysplastic syndromes. Celgene also submitted marketing applications for the multiple sclerosis drug ozanimod in the U.S. (again!) and the EU.
  • The year-ago quarter included a large acquisition expense, so non-GAAP earnings are a better measure of the company's year-over-year performance.
Doctor showing a report to a patient in a hospital bed

Image source: Getty Images.

What management had to say

Management didn't hold a conference call in association with the first-quarter results. But in the press release, Celgene's CEO Mark Alles noted that the company's "excellent operating performance continues to generate positive momentum into the expected closing of the Bristol-Myers Squibb transaction during the third quarter of 2019."

Looking forward

The company reaffirmed its guidance for 2019 product sales and earnings.

On the pipeline front, investors should look for clinical-trial data at the American Society of Clinical Oncology meeting in June -- for iberdomide in patients with multiple myeloma, liso-cel in patients with chronic lymphocytic leukemia, and Abraxane in patients with pancreatic cancer. An FDA approval for fedratinib in patients with myelofibrosis is expected by the beginning of September.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Stock Quote
Bristol Myers Squibb Stock Quote
Bristol Myers Squibb
$79.24 (0.13%) $0.10
Acceleron Pharma Stock Quote
Acceleron Pharma

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.